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ABSTRACT 
 
BACKGROUND AND AIMS Meta-analyses of randomized control trials investigating the association between 
incident diabetes and statin use showed an increased risk of new-onset diabetes (NOD) from 9% to 13% 
associated with statins. However, short follow-up period, unpowered sample size, and lack of pre-specified 
diagnostic criteria for diabetes detection could be responsible of an underestimation of this risk. We conducted 
a meta-analysis of published observational studies to evaluate the association between statins use and risk of 
NOD. 
METHODS AND RESULTS PubMed, EMBASE and MEDLINE databases were searched from inception to 
June 30, 2016 for cohort and case-control studies with risk of NOD in users vs nonusers, on ≥1000 subjects 
followed-up for ≥1 year. Two review authors assessed study eligibility and risk of bias and undertook data 
extraction independently. Pooled estimates were calculated by a random-effects model and between-study 
heterogeneity was tested and measured by I2 index. Furthermore, stratified analyses and the evaluation of 
publication bias were performed. Finally, the meta-analysis included 20 studies, 18 cohort and 2 case-control 
studies. Overall, NOD risk were higher in statin users than nonusers (RR 1.44; 95% CI 1.31-1.58). High 
between-study heterogeneity (I2=97%) was found. Estimates for all single statins showed a class effect, from 
rosuvastatin (RR 1.61; 1.30-1.98) to simvastatin (RR 1.38; 1.19-1.61).  
CONCLUSIONS The present meta-analysis confirms and reinforces the evidence of a diabetogenic effect by 
statins utilization. These observations confirm the need of a rigorous monitoring of patients taking statins, in 
particular pre-diabetic patients or patients presenting with established risk factors for diabetes. 
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INTRODUCTION 
 
Statin therapy represents the basis for the management of hypercholesterolemia and prevention 
of cardiovascular disease [1, 2]. Statins are generally safe and well tolerated. However, some studies 
have reported an association between statin therapy and the risk of new-onset diabetes.  
The first trial that evaluated the relationship between statin therapy and incident type 2 diabetes 
was the West of Scotland Coronary Prevention Study (WOSCOPS), which observed that pravastatin 
40 mg/day was associated with a 30% risk reduction for incident diabetes in a high-risk population of 
men with severe hypercholesterolemia [3]. Since then, several other studies have investigated this 
relationship, reporting controversial results. In fact, while some studies did not show any apparent 
effect of statins on the development of new diabetes [3-6], other investigations suggested an 
increased risk. Among these, the JUPITER (Justification for the Use of Statin in Prevention: an 
Intervention Trial Evaluating Rosuvastatin) trial, in which statin treatment was associated with small 
but significantly higher levels of glycated hemoglobin and incidence rates of diabetes [7], and an 
analysis of the WHI (Women’s Health Initiative), which reported an increased risk of diabetes mellitus 
in postmenopausal women taking statins [8]. These findings, together with observations from other 
clinical trials [9], led to hypothesize that statin therapy might trigger mechanisms leading to the 
development of diabetes. Several meta-analyses have thus evaluated data from available trials to 
define whether statin therapy may have a role in the development of type 2 diabetes, and observed 
an excess risk ranging from 9% up to 13% [10-14]. In particular, the increased risk of incident 
diabetes seems to be associated with high-intensity statin therapy [13]. A recent meta-analysis [15] 
showed that statins, as a class, significantly increase the risk of new-onset diabetes by 12% and that 
atorvastatin 80 mg was associated with the highest risk, followed by rosuvastatin, and simvastatin 80 
mg; high dose atorvastatin increased the risk of diabetes even when compared with other statins 
such as pravastatin, simvastatin or low-dose atorvastatin, in agreement with previous findings.  
Despite the risk of incident diabetes is low both in absolute and when compared with the 
significant reduction of cardiovascular events, the real weight of this risk is still undetermined. In 
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addition, randomized clinical trials (RCTs) have several limitations that might reduce the actual 
relevance of such increased risk [16]. RCTs in fact, did not include diabetes risk as a primary 
outcome; as a consequence, they could not reach adequate statistical power and sample size to find 
an association between statin use and diabetes risk. In addition, the absence of pre-specified criteria 
for diabetes diagnosis and detection, together with selection bias and dropout from studies, may lead 
to an underestimation of adverse cases. Finally, the relatively short follow-up period typical of RCTs 
or the possibility to prematurely terminate the trial once benefits are documented may preclude the 
detection of a chronic condition such as diabetes [16]. On the other hands, observational studies can 
be very large and have unlimited duration and follow-up, thus increasing the chance to detect 
adverse events with low incidence. Aim of the present study was thus to investigate the relationship 
between statin therapy and risk of incident diabetes by undertaking a meta-analysis of all available 
observational studies. 
 
 
METHODS 
 
This study was designed according to the Preferred Reporting Items for Systematic Reviews and 
Meta- Analyses (PRISMA) and the Meta-analysis of Observational Studies in Epidemiology 
(MOOSE) guidelines [17, 18].  
 
Study selection criteria 
We evaluated observational studies that reported or allowed to calculate risk of new-onset diabetes 
(NOD) with statin use.  
Studies were included if they met the following criteria: (1) the study examined risk of NOD for statin 
use vs non-use; (2) the study recruited 1000 participants or more; (3) follow-up was at least 1 year; 
(4) the risk estimate was reported as an odds ratio (OR), hazard ratio (HR) or relative risk (RR); (5) 
the 95% CI for the risk estimate was included. 
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Search strategy  
PubMed, MEDLINE, and EMBASE were searched from inception to 30 June 2016. The search 
strategy included keywords and MeSH terms relating to statins and type 2 diabetes.  
The keywords included: "hydroxymethylglutaryl-CoA reductase inhibitors" or "statins", "diabetes", 
“cohort study” or “case-control study”. One of the complete search strings is presented in 
Supplementals. 
We excluded studies published as abstracts. The review was restricted to original articles published 
in English. We also manually searched bibliographies of included studies as well as existing 
systematic reviews for any other articles that may be potentially suitable. 
 
Data extraction and evaluation 
Two authors independently scanned all titles and abstracts and excluded articles that clearly were not 
observational studies on the topic. We proceeded to assess full-text versions of potentially relevant 
articles and conducted more detailed checks against our eligibility criteria. Disagreements were 
resolved by discussion. 
We used preformatted tables (Table 1) to record study design and participant characteristics. Data 
extracted from observational studies were first author, year of publication, mean age range of 
participants, median follow-up time, drug exposure, and definition of NOD. We also extracted full 
adjusted estimates of risk along with 95% confidence intervals. 
A quality assessment of included studies was conducted for descriptive purposes and to evaluate 
potential differences according to quality criteria (Supplemental data). Two authors independently 
assessed study quality and resolved disagreements by further review and discussion. The 
methodological quality of the included case–control and cohort studies was evaluated using the 
validated Newcastle–Ottawa scale [19]. Scores range from zero to 10 stars. 
 
Statistical analysis  
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We pooled the estimates by using the fixed-effects and random-effects model according to 
DerSimonian & Laird method [20]. When a significant heterogeneity was found, the results from the 
random-effects model were presented. Between-study heterogeneity was tested by Cochrane’s Q 
test and measured with the I2 statistic (the proportion of between-study variability caused by 
heterogeneity) [21]. A stratified analysis was performed to assess if follow-up length, geographic area 
and propensity score matching could be the source of between study heterogeneity. 
Publication bias was evaluated visually through funnel plot and with the Egger’s test [22]. 
To evaluate to what extent obtained results could be influenced by a single study, an influence 
analysis was performed by omitting one study at a time. 
All tests were considered statistically significant for p-values less than 0.05. The analyses and the 
corresponding graphical visualization of forest and funnel plots were conducting using R package 
“metafor” (v 1.9-7). 
 
 
RESULTS 
 
Overall, 2,272 unique papers were retrieved from PUBMED, EMBASE and MEDLINE databases. 
Based on title/abstract, we selected 43 studies for full-text evaluation; among them, 20 observational 
studies fulfilling inclusion criteria were included in the final analyses (Figure 1) [8, 16, 23-40]. 
Characteristics of the included studies are shown in table 1. The years of publication range from 2004 
to June 2016; 2 of them were case-control studies [25, 35], 18 were cohort studies. The follow-up 
duration ranged between 2-20 years (median 7.2 years). Most of the studies were conducted in 
Europe (8 studies) and US (7 studies). The quality evaluation based on the Newcastle-Ottawa scale 
found an average score of 7, with 9 studies having score ≥8 (Supplemental Table 1). 
 
Overall, statin users have significantly greater risk of new-onset diabetes compared with non-users 
(RR 1.44; 95% CI, 1.31-1.58) (Figure 2). When considering single statins, we observed that users of 
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rosuvastatin and atorvastatin have the greatest increase in diabetes risk, being the relative risk 1.61 
(95% CI, 1.30-1.98) in rosuvastatin users and 1.49 (95% CI, 1.31-1.70) in atorvastatin users (Figure 
3). All reported estimates were obtained using the random-effect model since a large between-study 
heterogeneity was detected in all analyses (the I2 index was 97% for any statin).  
 
Stratified analysis 
Table 2 shows the results of the stratified analysis. Follow-up duration and propensity score matching 
do no seems to be sources of heterogeneity, since the between strata-specific estimates do not differ 
(p-values 0.173 and 0.195 respectively). On the contrary, an effect of the country was observed (p-
value <0.001), mainly due to the only study from New Zeland [26], which reported a higher 
association estimate compared with the other included studies; in fact, omitting this study, the test for 
the difference between group estimates provides a p-value of 0.197.  
 
Publication bias 
Evidence of publication bias was found for atorvastatin (p-value Egger’s test=0.03) but not for other 
statins or for use of any statin (Supplemental Figures 1 and 2). 
 
Influence analysis 
As reported above, the overall pooled estimate is 1.44 (95% CI, 1.31-1.58); when we performed the 
influence analysis by omitting one study at a time, we did not observe any significant change in the 
estimate pooled, suggesting that none of the included studies affects substantially the overall 
estimate (Supplemental Table 3). 
 
 
DISCUSSION 
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The results of our study show a 44% increased risk of new-onset diabetes among statin users 
compared with non-users; the analysis of single statins, indicating an increased risk varying from 
38% in simvastatin users up to 61% in rosuvastatin users, suggesting a class effect. A high between-
study heterogeneity was observed in our meta-analysis; the influence analysis shows a slight (but not 
significant) impact of the study of Currie et al., [26] on the pooled estimate for overall statin use. 
Analyses of influence and publication bias, although showed some evidence that individual papers 
and selective inclusion might have some effect respectively, do not seem to materially affect our 
estimates. 
Several clinical trials have reported an increased risk of new-onset diabetes in statin users, and 
meta-analyses of randomized clinical trials have confirmed such a finding [10-15]. In line with this, the 
present meta-analysis of available observational studies shows that subjects treated with statins are 
at higher risk of developing diabetes compared with patients not treated with statins. The increase of 
risk results much higher compared with previous meta-analyses of RCTs (44% vs 9-13%) [10, 11, 13, 
14, 41, 42], probably due to the different characteristics of RCTs and observational studies. 
Compared with RCTs, observational studies include, in fact, many more subjects followed for a 
longer time which may result in an increased chance to detect adverse events, in particular those that 
may require several years to occur or be detected, such as diabetes [16]. Furthermore, the rigorous 
selection of subjects recruited for an RCT may lead to the exclusion of individuals at higher risk for 
adverse events [16], and this may result in an underestimation of adverse events, in particular if their 
incidence is low. In addition, RCTs may have an early stop than planned due to exciding benefits, as 
they are designed and powered to detect efficacy, and this may further reduce the chance to detect 
adverse events.  
On the other hand, despite more generalizable than RCTs, due to the lack of subject selection, 
observational studies may have some limitations. In fact, while in RCTs randomization leads to a 
comparable distribution of known and unknown factors potentially affecting any observable variable in 
the compared groups, this is not possible in observational studies due to the absence of 
randomization, and can result in biases.  
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A major limitation in the interpretation of results from observational studies is the “indication bias”; in 
our case, patients treated with statins may be more prone to develop diabetes than those not 
exposed to statin therapies. Pre-diabetes, i.e. the most important risk factor for type 2 diabetes, is 
often associated with dyslipidaemia and this increases the chance that subjects with pre-diabetes will 
be treated with statins; moreover, statin-treated subjects tend to be sicker than non-statin users, and 
thus they may develop diabetes with higher frequency independently of statin use [43]. Investigators 
attempted to obtain comparable groups by a range of methods including nested sampling, controlling 
for potential confounders and propensity score matching. In some studies, risk estimates were 
adjusted for lipid levels [27, 34, 39] or propensity score was calculated for matching or adjustment 
purposes [8, 16, 25, 29, 30, 34, 36-39, 44]. For example, Jick et al. [35] limited the study population 
to untreated and statin treated hyperlipidaemics to minimize the effects of hyperlipidaemia itself on 
the development of diabetes. Also in the study by Corrao et al. [45], the risk of incident diabetes 
showed a continuous increasing trend with increasing levels of adherence, compared to dyslipidemic 
patients with low adherence, supporting the role of the drug, in addition to the underlying disease. 
This finding is further supported by several randomized clinical trials in which an increased diabetes 
risk among statin users was observed, and randomization is particularly efficient in controlling for 
selection bias and confounding.  
Another potential bias in observational studies is the detection bias, which occurs when a 
phenomenon is more likely to be observed for a particular set of study subjects. In our case, we can 
speculate that people prescribed a therapy are more likely to be clinically evaluated, thus increasing 
their chance of being diagnosed with diabetes. Despite this, in the studies in which adjustment or 
stratification by frequency of cholesterol tests and outpatient visits was performed the increase in 
NOD risk was still present [35, 45, 46]. In addition, patients prescribed statins have a higher risk of 
new-onset diabetes compared with patients prescribed diclofenac, suggesting that in these two 
groups of patients, having the same chance to be clinically evaluated, the increased NOD risk can be 
attributed to statins [26]; moreover, when patients treated with statins were evaluated for the 
incidence of peptic ulcer, considered as a negative outcome control for statin treatment, a null 
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association was observed, as expected, suggesting that the observed increase of NOD risk was not 
due to bias [27, 46].  
In our meta-analysis, we observed little publication bias for atorvastatin. In particular it seems that 
studies reporting a statistically significant increased risk of new-onset diabetes are more likely 
published. Since the effect of publication bias was detected exclusively for this statin, it is possible 
that the effect of atorvastatin may have been overestimated, but it is also reasonable that atorvastatin 
increases the NOD risk similarly to other statins. 
 
Several studies were performed to identify the biological mechanisms explaining the diabetogenic 
effect of statins. As first, the inhibition of the statin target 3-hydroxy-methylglutaryl-CoA reductase 
(HMGCR) seems to play a role [47]. In fact, the analysis of the single nucleotide polymorphism (SNP) 
rs17238484 in the HMGCR gene showed that the rs17238484-G allele was associated with lower 
LDL-C levels, higher plasma levels of insulin and glucose, greater waist and hip circumference and 
increased body weight [47]; another SNP, rs12916, showed similar associations with these 
parameters [47]. Thus, both SNPs seem to be associated with increased risk of diabetes, 
independently of statin therapy use. In agreement with this observation, statin treatment in 
randomized trials is associated with bodyweight gain and increased risk of incident diabetes [47].  
Besides, the LDL-C-lowering effect of statins may itself increase the risk of diabetes among statin 
users. In fact, low LDL-C levels are associated with an increased risk of developing new diabetes in 
subjects not treated with lipid-modifying therapies [48], and this finding is supported by several 
independent observations. As first, despite at clinical level dyslipidemia is associated with 
hyperglycemia and insulin resistance, the genetic predisposition to dyslipidemia is associated with 
lower levels of diabetes-related parameters, including fasting plasma glucose, glycated hemoglobin 
and HOMA-IR, suggesting pleiotropic effects of lipid genes on these parameters independent of 
blood lipid levels [49]. In addition, genetically higher circulating LDL-C levels are associated with a 
lower risk of diabetes, as shown by either the analysis of SNPs on genes related to lipid metabolism 
[50] or by the observation of a lower prevalence of type 2 diabetes among patients with familial 
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hypercholesterolemia compared with unaffected relatives [51], as well as in FH patients with LDLR 
negative mutations compared with FH patients with LDLR defective mutations [51].  
Other mechanisms may however contribute to the new-onset diabetes induced by statins [52]. 
Several in vitro studies suggest that statin treatment may be detrimental for pancreatic ß-cell function. 
In fact, statins dose-dependently induce ß-cell damage and smooth muscle cell insulin resistance 
[53], reduce glucose transporter 4 (GLUT4) expression, a transporter responsible for the uptake of 
glucose in peripheral cells [53-55], reduce insulin signal transduction [54, 56, 57], inhibit adipocyte 
differentiation, thus leading to accumulation of cells unable to secrete insulin-sensitizing hormone and 
to insulin resistance [54], and reduce pancreatic ß-cell function [58-60]. By inhibiting the cholesterol 
synthesis pathway, statins also inhibit the synthesis of several other products that are relevant for 
normal cell functions, such as those involved in glucose homeostasis [52]. Additional mechanisms, 
such as the link between statin treatment and specific microRNAs involved in the reduction of insulin 
secretion, are currently being investigated [52]. 
 
In summary, our meta-analysis of observational studies confirms and reinforces the evidence that 
statins possess diabetogenic properties; all considered statins significantly increase the risk of 
incident diabetes, independently of their chemico-physical characteristics, suggesting thus a class 
effect. Some authors [61] tried to quantify the excess risk of cardiovascular events derived from the 
increased incidence of statins-associated diabetes, concluding with the confirmation of a favorable 
risk-benefit ratio of these drugs, due to the large reduction in cardiovascular risk. Although the 
estimates need to be updated with the higher risk from observational studies, we should consider that 
the diabetic patient is not only characterized by an increased cardiovascular risk, but also by other 
complications, the need for drugs, and worse quality of life. These aspects are difficult to quantify, but 
might result in a clinical and economic impact. These observations confirm the need of a rigorous 
monitoring of patients taking statins, in particular pre-diabetic patients or patients presenting with 
established risk factors for diabetes. 
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Figure 1 Flow-chart for the selection of eligible observational studies 
Figure 2 Meta-analysis of risk of new onset diabetes for any statin use vs non use 
Figure 3 Meta-analysis of risk of new onset diabetes for specific statin use vs non use 
 
 
REFERENCES  
[1] Cholesterol Treatment Trialists C, Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, et al. Efficacy and safety 
of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 
randomised trials. Lancet. 2015;385:1397-405. 
[2] Cholesterol Treatment Trialists C, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of 
more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. 
Lancet. 2010;376:1670-81. 
[3] Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, et al. Pravastatin and the development of diabetes 
mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 
2001;103:357-62. 
[4] Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events 
with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas 
Coronary Atherosclerosis Prevention Study. Jama. 1998;279:1615-22. 
[5] Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial 
infarction: do stopped trials contribute to overall knowledge? GISSI Prevenzione Investigators (Gruppo Italiano per lo 
Studio della Sopravvivenza nell'Infarto Miocardico). Italian heart journal : official journal of the Italian Federation of 
Cardiology. 2000;1:810-20. 
13 
[6] Keech A, Colquhoun D, Best J, Kirby A, Simes RJ, Hunt D, et al. Secondary prevention of cardiovascular events with 
long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes care. 
2003;26:2713-21. 
[7] Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr., Kastelein JJ, et al. Rosuvastatin to prevent vascular 
events in men and women with elevated C-reactive protein. The New England journal of medicine. 2008;359:2195-207. 
[8] Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J, et al. Statin use and risk of 
diabetes mellitus in postmenopausal women in the Women's Health Initiative. Archives of internal medicine. 
2012;172:144-52. 
[9] Park ZH, Juska A, Dyakov D, Patel RV. Statin-associated incident diabetes: a literature review. The Consultant 
pharmacist : the journal of the American Society of Consultant Pharmacists. 2014;29:317-34. 
[10] Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing 
type 2 diabetes: a meta-analysis. Diabetes care. 2009;32:1924-9. 
[11] Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a 
collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735-42. 
[12] Mills EJ, Wu P, Chong G, Ghement I, Singh S, Akl EA, et al. Efficacy and safety of statin treatment for cardiovascular 
disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM : monthly journal of the 
Association of Physicians. 2011;104:109-24. 
[13] Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose 
compared with moderate-dose statin therapy: a meta-analysis. Jama. 2011;305:2556-64. 
[14] Cai R, Yuan Y, Zhou Y, Xia W, Wang P, Sun H, et al. Lower intensified target LDL-c level of statin therapy results in a 
higher risk of incident diabetes: a meta-analysis. PloS one. 2014;9:e104922. 
[15] Thakker D, Nair S, Pagada A, Jamdade V, Malik A. Statin use and the risk of developing diabetes: a network meta-
analysis. Pharmacoepidemiology and drug safety. 2016. 
[16] Mansi I, Frei CR, Wang CP, Mortensen EM. Statins and New-Onset Diabetes Mellitus and Diabetic Complications: A 
Retrospective Cohort Study of US Healthy Adults. Journal of general internal medicine. 2015;30:1599-610. 
[17] Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic 
review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic reviews. 2015;4:1. 
[18] Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in 
epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. Jama. 
2000;283:2008-12. 
[19] Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing 
the quality if nonrandomized studies in meta-analyses. . 
[20] DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88. 
[21] Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Bmj. 2003;327:557-60. 
[22] Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Bmj. 
1997;315:629-34. 
[23] Bhattacharya R, Ajmera M, Bhattacharjee S, Sambamoorthi U. Use of antidepressants and statins and short-term 
risk of new-onset diabetes among high risk adults. Diabetes research and clinical practice. 2014;105:251-60. 
[24] Cederberg H, Stancakova A, Yaluri N, Modi S, Kuusisto J, Laakso M. Increased risk of diabetes with statin treatment 
is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. 
Diabetologia. 2015;58:1109-17. 
[25] Chen CW, Chen TC, Huang KY, Chou P, Chen PF, Lee CC. Differential impact of statin on new-onset diabetes in 
different age groups: a population-based case-control study in women from an asian country. PloS one. 2013;8:e71817. 
[26] Currie O, Mangin D, Williman J, McKinnon-Gee B, Bridgford P. The comparative risk of new-onset diabetes after 
prescription of drugs for cardiovascular risk prevention in primary care: a national cohort study. BMJ open. 
2013;3:e003475. 
[27] Danaei G, Garcia Rodriguez LA, Fernandez Cantero O, Hernan MA. Statins and risk of diabetes: an analysis of 
electronic medical records to evaluate possible bias due to differential survival. Diabetes care. 2013;36:1236-40. 
[28] Izzo R, de Simone G, Trimarco V, Giudice R, De Marco M, Di Renzo G, et al. Primary prevention with statins and 
incident diabetes in hypertensive patients at high cardiovascular risk. Nutrition, metabolism, and cardiovascular 
diseases : NMCD. 2013;23:1101-6. 
[29] Lichtenstein KA, Hart RL, Wood KC, Bozzette S, Buchacz K, Brooks JT, et al. Statin Use Is Associated With Incident 
Diabetes Mellitus Among Patients in the HIV Outpatient Study. Journal of acquired immune deficiency syndromes. 
2015;69:306-11. 
[30] Macedo AF, Douglas I, Smeeth L, Forbes H, Ebrahim S. Statins and the risk of type 2 diabetes mellitus: cohort study 
using the UK clinical practice pesearch datalink. BMC cardiovascular disorders. 2014;14:85. 
14 
[31] Radford NB, DeFina LF, Barlow CE, Kerr A, Chakravorty R, Khera A, et al. Effect of fitness on incident diabetes from 
statin use in primary prevention. Atherosclerosis. 2015;239:43-9. 
[32] Zaharan NL, Williams D, Bennett K. Statins and risk of treated incident diabetes in a primary care population. British 
journal of clinical pharmacology. 2013;75:1118-24. 
[33] Calza L, Colangeli V, Magistrelli E, Manfredi R, Bon I, Re MC, et al. No correlation between statin exposure and 
incident diabetes mellitus in HIV-1-infected patients receiving combination antiretroviral therapy. HIV medicine. 2016. 
[34] Castro MR, Simon G, Cha SS, Yawn BP, Melton LJ, 3rd, Caraballo PJ. Statin Use, Diabetes Incidence and Overall 
Mortality in Normoglycemic and Impaired Fasting Glucose Patients. Journal of general internal medicine. 2016;31:502-8. 
[35] Jick SS, Bradbury BD. Statins and newly diagnosed diabetes. British journal of clinical pharmacology. 2004;58:303-9. 
[36] Lin ZF, Wang CY, Shen LJ, Hsiao FY, Lin Wu FL. Statin Use and the Risk for Incident Diabetes Mellitus in Patients with 
Acute Coronary Syndrome after Percutaneous Coronary Intervention: A Population-Based Retrospective Cohort Study in 
Taiwan. Canadian journal of diabetes. 2016;40:264-9. 
[37] Olotu BS, Shepherd MD, Novak S, Lawson KA, Wilson JP, Richards KM, et al. Use of Statins and the Risk of Incident 
Diabetes: A Retrospective Cohort Study. American journal of cardiovascular drugs : drugs, devices, and other 
interventions. 2016;16:377-90. 
[38] Rha SW, Choi BG, Seo HS, Park SH, Park JY, Chen KY, et al. Impact of Statin Use on Development of New-Onset 
Diabetes Mellitus in Asian Population. The American journal of cardiology. 2016;117:382-7. 
[39] van de Woestijne AP, van der Graaf Y, Westerink J, Nathoe HM, Visseren FL. Effect of statin therapy on incident 
type 2 diabetes mellitus in patients with clinically manifest vascular disease. The American journal of cardiology. 
2015;115:441-6. 
[40] Wang KL, Liu CJ, Chao TF, Huang CM, Wu CH, Chen SJ, et al. Statins, risk of diabetes, and implications on outcomes 
in the general population. Journal of the American College of Cardiology. 2012;60:1231-8. 
[41] Coleman CI, Reinhart K, Kluger J, White CM. The effect of statins on the development of new-onset type 2 diabetes: 
a meta-analysis of randomized controlled trials. Current medical research and opinion. 2008;24:1359-62. 
[42] Navarese EP, Buffon A, Andreotti F, Kozinski M, Welton N, Fabiszak T, et al. Meta-analysis of impact of different 
types and doses of statins on new-onset diabetes mellitus. The American journal of cardiology. 2013;111:1123-30. 
[43] Schrom JR, Caraballo PJ, Castro MR, Simon GJ. Quantifying the effect of statin use in pre-diabetic phenotypes 
discovered through association rule mining. AMIA  Annual Symposium proceedings / AMIA Symposium AMIA 
Symposium. 2013;2013:1249-57. 
[44] Park JY, Rha SW, Choi B, Choi JW, Ryu SK, Kim S, et al. Impact of low dose atorvastatin on development of new-
onset diabetes mellitus in Asian population: Three-year clinical outcomes. International journal of cardiology. 
2015;184:502-6. 
[45] Corrao G, Ibrahim B, Nicotra F, Soranna D, Merlino L, Catapano AL, et al. Statins and the risk of diabetes: evidence 
from a large population-based cohort study. Diabetes care. 2014;37:2225-32. 
[46] Arfe A, Corrao G. Tutorial: strategies addressing detection bias were reviewed and implemented for investigating 
the statins-diabetes association. Journal of clinical epidemiology. 2015;68:480-8. 
[47] Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes MV, Engmann JE, Shah T, et al. HMG-coenzyme A reductase 
inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet. 
2015;385:351-61. 
[48] Andersson C, Lyass A, Larson MG, Robins SJ, Vasan RS. Low-density-lipoprotein cholesterol concentrations and risk 
of incident diabetes: epidemiological and genetic insights from the Framingham Heart Study. Diabetologia. 
2015;58:2774-80. 
[49] Li N, van der Sijde MR, LifeLines Cohort Study G, Bakker SJ, Dullaart RP, van der Harst P, et al. Pleiotropic effects of 
lipid genes on plasma glucose, HbA1c, and HOMA-IR levels. Diabetes. 2014;63:3149-58. 
[50] Fall T, Xie W, Poon W, Yaghootkar H, Magi R, Consortium G, et al. Using Genetic Variants to Assess the Relationship 
Between Circulating Lipids and Type 2 Diabetes. Diabetes. 2015;64:2676-84. 
[51] Besseling J, Kastelein JJ, Defesche JC, Hutten BA, Hovingh GK. Association between familial hypercholesterolemia 
and prevalence of type 2 diabetes mellitus. Jama. 2015;313:1029-36. 
[52] Brault M, Ray J, Gomez YH, Mantzoros CS, Daskalopoulou SS. Statin treatment and new-onset diabetes: a review of 
proposed mechanisms. Metabolism: clinical and experimental. 2014;63:735-45. 
[53] Zhao W, Zhao SP. Different effects of statins on induction of diabetes mellitus: an experimental study. Drug design, 
development and therapy. 2015;9:6211-23. 
[54] Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T. Effects of statins on the adipocyte maturation and 
expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia. 2006;49:1881-92. 
[55] Khan T, Hamilton MP, Mundy DI, Chua SC, Scherer PE. Impact of simvastatin on adipose tissue: pleiotropic effects in 
vivo. Endocrinology. 2009;150:5262-72. 
15 
[56] McGuire TF, Xu XQ, Corey SJ, Romero GG, Sebti SM. Lovastatin disrupts early events in insulin signaling: a potential 
mechanism of lovastatin's anti-mitogenic activity. Biochemical and biophysical research communications. 1994;204:399-
406. 
[57] Takaguri A, Satoh K, Itagaki M, Tokumitsu Y, Ichihara K. Effects of atorvastatin and pravastatin on signal 
transduction related to glucose uptake in 3T3L1 adipocytes. Journal of pharmacological sciences. 2008;107:80-9. 
[58] Brunham LR, Kruit JK, Hayden MR, Verchere CB. Cholesterol in beta-cell dysfunction: the emerging connection 
between HDL cholesterol and type 2 diabetes. Current diabetes reports. 2010;10:55-60. 
[59] Brunham LR, Kruit JK, Pape TD, Timmins JM, Reuwer AQ, Vasanji Z, et al. Beta-cell ABCA1 influences insulin 
secretion, glucose homeostasis and response to thiazolidinedione treatment. Nature medicine. 2007;13:340-7. 
[60] Kruit JK, Kremer PH, Dai L, Tang R, Ruddle P, de Haan W, et al. Cholesterol efflux via ATP-binding cassette 
transporter A1 (ABCA1) and cholesterol uptake via the LDL receptor influences cholesterol-induced impairment of beta 
cell function in mice. Diabetologia. 2010;53:1110-9. 
[61] Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al. Interpretation of the evidence for the 
efficacy and safety of statin therapy. Lancet. 2016. 
 
 
 
16 
Table 1 Selected characteristics of 20 observational studies included in the meta-analysis 
First author 
(Year) 
Design Study 
duration 
(year) 
NOD 
definition 
Mean 
age 
(year) 
Exposure OR/RR/HR  
(95% CI) 
Adjustment 
Jick SS (2004) 
Nested 
case-
control 
11 
diagnosis 
AND drugs 
59.2 
Any statin 1.1 (0.8-1.4) Body mass index, hypertension, steroid use, smoking and 
the number of GP visits within 3 years preceding the index 
date 
Pravastatin 0.7 (0.4-1.2) 
Simvastatin 1.0 (0.7-1.3) 
Culver A 
(2012) 
Cohort 9 
self-
reported 
63.2 
Any statin 1.48 (1.38-1.59) 
Age, race/ethnicity, education, cigarette smoking, BMI, 
physical activity, alcohol intake, energy intake, family 
history of diabetes, hormone therapy use, study arms, and 
self-report of cardiovascular disease at baseline 
Simvastatin 1.41 (1.25-1.61) 
Fluvastatin 1.61 (1.35-1.92) 
Atorvastatin 1.61 (1.26-2.06) 
Pravastatin 1.63 (1.43-1.87) 
Danaei G 
(2012) 
Cohort 9 
diagnosis 
OR drugs 
63.2 
Any statin 1.14 (1.09-1.19) Gender, townsend deprivation score, age, LDL cholesterol, 
HDL cholesterol, BMI, systolic blood pressure, alcohol use, 
doctor visits, referrals, hospitalizations, alcoholism, 
smoking prevalence, hypertension, antihypertensive use, 
NSAIDs use, aspirin use, other lipid-lowering drugs use, b-
Blockers use, hormone replacement therapy, chronic 
obstructive pulmonary disease, oral steroids use, inhaled 
steroids use, atrial fibrillation, depression, antidepressant 
use, hypothyroidism, osteoporosis, history of transplant, 
immunosuppression therapy, psoriasis, rheumatoid 
arthritis, chemotherapy, radiotherapy, chronic pancreatitis 
Simvastatin 1.14 (1.09-1.20) 
Atorvastatin 1.22 (1.12-1.32) 
Pravastatin 1.01 (0.84-1.21) 
Rosuvastatin 1.11 (0.89-1.38) 
Fluvastatin 1.02 (0.69-1.50) 
Wang KL 
(2012) 
Cohort 8 
diagnosis 
AND drugs 
63.0 Any statin 1.15 (1.08-1.22) Unadjusted 
Chen CW 
(2013) 
Case-
control 
2 diagnosis 61.3 Atorvastatin 2.80 (1.74-4.49) Gender, hypertension, coronary heart disease, diabetes, 
hyperlipidemia, atrial fibrillation, chronic kidney disease, 
obesity, peripheral arterial disease, non-statin lipid lowering 
medications, aspirin, angiotensin-converting enzyme 
inhibitors, triglyceride-lowering medications, hormone 
therapy, socioeconomic status, geographic region and 
urbanization level of residence 
Rosuvastatin 4.69 (2.78-7.92) 
Simvastatin 4.09 (2.52-6.64) 
Pravastatin 3.41 (1.66-7.04) 
Currie O 
(2013) 
Cohort 6 drugs NA Any statin 3.31 (2.56-4.30) Age, sex, and ethnicity 
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Izzo R (2013) Cohort 4.7 
biochemical
s AND 
(diagnosis 
OR drugs) 
58.6 Any statin 1.03 (0.79-1.35) 
Age, gender, use of statins before diagnosis of diabetes, 
duration of hypertension and baseline parameters 
Zaharan 
NL(2013) 
Cohort 6/9 drugs NA 
Any statin 1.20 (1.17-1.23) 
Gender, age groups, prescriptions of oral corticosteroids, 
antipsychotics, antihypertensive drugs, medications for 
ischaemic heart disease, anti-obesity and other lipid 
modifying agents. 
Atorvastatin 1.25 (1.21-1.28) 
Pravastatin 1.02 (0.98-1.06) 
Rosuvastatin 1.42 (1.33-1.52) 
Simvastatin 1.14 (1.06-1.23) 
Fluvastatin 1.04 (0.91-1.18) 
Bhattacharya 
R (2014) 
Cohort 2 diagnosis NA Any statin 1.62 (1.25-2.09) 
Antidepressants–statins use; presence of depression; life 
style risk factors - BMI categories, lack of physical activity, 
smoking status, age groups, gender; race/ethnicity; poverty 
status, insurance status 
Cederberg H 
(2014) 
Cohort 5.9 
biochemical
s OR 
diagnosis 
OR drugs 
57.1 Any statin 1.46 (1.22-1.74) 
Age, BMI, waist circumference, physical activity, smoking, 
alcohol intake, family history of diabetes and beta-blocker 
and diuretic treatment  
Macedo AF 
(2014) 
Cohort 20 diagnosis 62.3 Any statin 1.57 (1.54-1.59) 
Adjusted for age, gender, propensity score, post index date 
diagnosis of hepatic disease and family history of diabetes 
Lichtenstein 
KA (2015) 
Cohort 10 
biochemical
s OR drugs 
40.0 Any statin 1.14 (1.02-1.27) 
Age, sex, race/ethnicity, exposure to antiretroviral therapy, 
prevalent hepatitis C, BMI, and cumulative use of protease 
inhibitors 
Mansi I (2015) Cohort 10 diagnosis 53.0 Any statin 1.87 (1.67–2.01) 
Propensity score (age, gender, smoking, alcohol-related 
disorders, substance-related disorders, charlson 
comorbidity score, overweight/obese, hypertension, acute 
kidney injury, asthma, gastrointestinal hemorrhage, 
gastritis/duodenitis, nonspecific chest pain, heart disease 
not otherwise specified, osteoarthritis, arthropathy, and 
back disorder, sprains, strains, and trauma-related joint 
disorders, fracture of bone, osteoporosis, rehabilitation 
care, fitting of prostheses, and adjustment of devices, 
number of inpatient admissions, number of outpatient 
medical encounters, number of encounters for 
immunization, receive immunization and screening for 
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infectious disease, beta-blocker, diuretic, ACE-Is/ARBs, 
calcium channel blocker, proton pump inhibitors, aspirin, 
NSAIDs, bisphosphonates, sedatives, SSRI, antipsychotic, 
tricyclic anti-depressants, systemic corticosteroids, 
hormone replacement therapy, testosterone, cytochrome 
p450, non-statin lipid lowering drugs, oral hypoglycemic, 
antiplatelet agents (other than aspirin), warfarin) 
Radford NB 
(2015) 
Cohort 3 
biochemical
s OR drugs 
OR self-
reported 
48.2 Any statin 2.04 (1.30-3.22) 
Statin use at visit 2, age, gender, chronic renal failure, and 
metabolic syndrome at index visit 
van de 
Woestijne AP 
(2015) 
Cohort 15 
self-
reported 
(with cross-
validation) 
59.0 Any statin 1.66 (1.14-2.42) 
Age, gender and propensity score (age, sex, localisation of 
vascular disease, body mass index, HDL-cholesterol, 
plasma triglycerides, systolic blood pressure, plasma 
glucose, platelet inhibitors, blood pressure lowering 
medication, smoking, eGFR and time since inclusion) 
Calza L (2016) Cohort 5.2 
biochemical
s OR drugs 
44.5 Any statins 1.09 (0.76-1.49) 
Age, sex, race, chronic hepatitis C, body mass index, 
fasting serum concentration of triglycerides, cumulative 
exposure to combination antiretroviral therapy (cART) and 
cumulative exposure to specific antiretroviral agents 
Castro MR 
(2016) 
Cohort 6 diagnosis 55.7 Any statins 1.19 (1.05-1.35) 
Lipid panel (LDL, HDL, triglycerides), blood pressure, body 
mass index, the use of hypertension drugs and 
demographics (age and gender) 
Lin ZF (2016) Cohort 3.1 diagnosis 65.4 
Any statin 1.27 (1.14-1.41) 
Age, sex, various comorbidities (ischemic heart disease, 
cerebrovascular disease, heart failure, hypertension, renal 
disease, hyperlipidemia, liver disease and peripheral 
vascular disease) and comedication 
Atorvastatin 1.30 (1.13-1.50) 
Pravastatin 1.71 (1.12-2.60) 
Rosuvastatin 1.42 (1.23-1.64) 
Simvastatin 1.60 (1.10-2.32) 
Fluvastatin 1.38 (1.07-1.80) 
Olotu BS 
(2016) 
Cohort 1.3 diagnosis 46.3 
Any statin 2.07 (1.77-2.42) 
Age, sex, hyperlipidemia, obesity, hypertension, use of 
diabetogenic medications, and Charlson Comorbidity Index 
score 
Atorvastatin 1.95 (1.62-2.35) 
Pravastatin 1.40 (1.04-1.87) 
Rosuvastatin 1.75 (1.19-2.56) 
Simvastatin 1.79 (1.43-2.24) 
Fluvastatin 1.95 (1.28-2.96) 
19 
Rha SW 
(2016) 
Cohort 3 
biochemical
s OR drugs 
60.2 
Any statin 1.99 (1.36-2.92) 
M ale gender, age, history of risk (hypertension, coronary 
artery disease, coronary spasm, dyslipidemia, angiotensin 
receptor blockers, angiotensin-converting enzyme 
inhibitors, calcium channel blockers, b blockers, diuretics, 
nitrates, and statins 
Atorvastatin 2.09 (1.27-3.44) 
Pravastatin 2.88 (1.50-5.55) 
Rosuvastatin 2.13 (1.04-4.38) 
Simvastatin 0.99 (0.49-2.02) 
Fluvastatin 2.54 (1.03-6.21) 
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Table 2 Stratified analyses based on duration of follow-up, on geographic areas and propensity 
score matching 
Strata N Q Q p-value I
2
 RR (95%CI) p-value 
Overall 19 611.89 <0.0001 0.971 1.44 (1.31-1.58) 
 
Lenght of follow-up 
      
<7.2 years 10 88.845 <0.0001 0.899 1.58 (1.3-1.94) 
0.173 
≥7.2 years 9 522.19 <0.0001 0.985 1.34 (1.18-1.52) 
Country 
      
Asia 4 11.723 0.0084 0.744 1.32 (1.12-1.56) 
<0.0001 
Europe 8 433.93 <0.0001 0.984 1.27 (1.09-1.47) 
USA 7 77.404 <0.0001 0.923 1.55 (1.3-1.85) 
NZL 1 - - - 3.31 (2.55-4.29) 
PS matching  
(cohort studies only)       
No 13 159.51 <0.0001 0.925 1.43 (1.29-1.59) 
0.195 
Yes 6 30.895 <0.0001 0.871 1.61 (1.39-1.86) 
N: number of studies included in each stratum, Q and Q p-value: value of the Q statistics and corresponding 
p-value of the test, I
2
: value of the I
2
 index, RR (95%CI): value of the stratum-specific relative risk estimate 
and corresponding 95% confidence interval, p-value: p-value of the test for between-strata difference in the 
estimates. 
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